Primary care physician use across the breast cancer care continuum: CanIMPACT study using Canadian administrative data

• Published in: Canadian family physician 2016-10, Vol.62 (10), p.e589-e598
• Main Authors: Jiang, Li, Lofters, Aisha, Moineddin, Rahim, Decker, Kathleen, Groome, Patti, Kendell, Cynthia, Krzyzanowska, Monika, Li, Dongdong, McBride, Mary L, Mittmann, Nicole, Porter, Geoff, Turner, Donna, Urquhart, Robin, Winget, Marcy, Zhang, Yang, Grunfeld, Eva
• Format: Article
• Language: English
• Subjects: Adult; Aged; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - therapy; British Columbia - epidemiology; Comorbidity; Continuity of Patient Care - organization & administration; Databases, Factual; Female; Humans; Manitoba - epidemiology; Medical treatment; Middle Aged; Office Visits - statistics & numerical data; Ontario - epidemiology; Physicians; Physicians, Primary Care; Retrospective Studies
• ISSN: 0008-350X; 1715-5258

To describe primary care physician (PCP) use and continuity of PCP care across the breast cancer care continuum. Population-based, retrospective cohort study using provincial cancer registries linked to health administrative databases. British Columbia, Manitoba, and Ontario. All women with incident invasive breast cancer from 2007 to 2012 in Manitoba and Ontario and from 2007 to 2011 in British Columbia. The number and proportions of visits to PCPs were determined. Continuity of care was measured using the Usual Provider of Care index calculated as the proportion of visits to the most-often-visited PCP in the 6 to 30 months before a breast cancer diagnosis (baseline) and from 1 to 3 years following a breast cancer diagnosis (survivorship). More than three-quarters of patients visited their PCPs 2 or more times during the breast cancer diagnostic period, and more than 80% of patients had at least 1 PCP visit during breast cancer adjuvant treatment. Contact with the PCP decreased over time during breast cancer survivorship. Of the 3 phases, women appeared to be most likely to not have PCP contact during adjuvant treatment, with 10.7% (Ontario) to 18.7% (British Columbia) of women having no PCP visits during this phase. However, a sizable minority of women had at least monthly visits during the treatment phase, particularly in Manitoba and Ontario, where approximately a quarter of women saw a PCP at least monthly. We observed higher continuity of care with PCPs in survivorship (compared with baseline) in all provinces. Primary care physicians were generally involved throughout the breast cancer care continuum, but the level of involvement varied across care phases and by province. Future interventions will aim to further integrate primary and oncology care.